RxDoctor Payments Data

Jeffrey Rednor, DO

Family Medicine · Trenton, NJNPI 1184648149

Payments from drug & device makers

$1,611in general payments, 2019–2025

Across 99 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$474
  • Lilly USA, LLC$303
  • AstraZeneca$266
  • Kowa Pharmaceuticals America, Inc.$143
  • Novo Nordisk$135
  • Amgen$122
  • plus $168 from 5 others

What the payments were for

  • Food & beverage$1,59299%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,611 in reported general payments places this provider in the 70th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$81,184
Medicare patients
245
Services billed
2,636

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$83,651
EliquisApixaban57$61,006
JanuviaSitagliptin Phosphate32$49,633
FarxigaDapagliflozin Propanediol34$36,730
MounjaroTirzepatide26$36,057
XareltoRivaroxaban14$23,432
MyrbetriqMirabegron21$16,748
Repatha SureclickEvolocumab12$11,424
Breo ElliptaFluticasone/Vilanterol16$6,351
Valsartan134$5,373
Rosuvastatin Calcium334$4,381
Nebivolol Hcl55$4,049
Esomeprazole Magnesium34$2,984
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid21$2,979
SynthroidLevothyroxine Sodium31$2,884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$135$83,65164 claims
PfizerEliquis$53$61,00657 claims
MerckJanuvia$27$49,63332 claims
AstraZenecaFarxiga$266$36,73034 claims
Lilly USA, LLCMounjaro$303$36,05726 claims
Johnson & JohnsonXarelto$474$23,43214 claims
GSKBreo Ellipta$14$6,35116 claims
AbbVieSynthroid$60$2,88431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Trenton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →